Cargando…

Outcomes following mepolizumab treatment discontinuation: real-world experience from an open-label trial

Limited information is available on the clinical course of patients with severe asthma following discontinuation of biologic treatment. Therefore, a post hoc analysis was conducted in patients with severe eosinophilic asthma who participated in the COSMOS trial, where patients received mepolizumab f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ortega, Hector, Lemiere, Catherine, Llanos, Jean-Pierre, Forshag, Mark, Price, Robert, Albers, Frank, Yancey, Steven, Castro, Mario
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558891/ https://www.ncbi.nlm.nih.gov/pubmed/31198427 http://dx.doi.org/10.1186/s13223-019-0348-z

Ejemplares similares

Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs
por: Llanos, Jean-Pierre, et al.
Publicado: (2020)

Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment
por: Magnan, A., et al.
Publicado: (2016)

Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials
por: Lemiere, Catherine, et al.
Publicado: (2021)

Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study
por: Llanos, Jean-Pierre, et al.
Publicado: (2019)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
por: Yancey, Steven W., et al.
Publicado: (2019)

Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions
por: Gibson, Peter G., et al.
Publicado: (2021)

Economic Burden of Illness Among Patients with Severe Asthma in a Managed Care Setting
por: Chastek, Benjamin, et al.
Publicado: (2016)

Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
por: Prazma, Charlene M, et al.
Publicado: (2021)

Eosinophil‐derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma
por: Howarth, Peter, et al.
Publicado: (2020)

Update: Mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use
por: Albers, Frank C., et al.
Publicado: (2019)

Response to mepolizumab treatment is sustained across 4-weekly dosing periods
por: Pavord, Ian D., et al.
Publicado: (2020)

Mepolizumab and COPD in Real Life
por: Revuelta-Salgado, Fernando, et al.
Publicado: (2021)

Efficacy and safety of mepolizumab in Korean patients with severe eosinophilic asthma from the DREAM and MENSA studies
por: Kim, Mi-Kyeong, et al.
Publicado: (2021)

Dose-Response Relationship Between Long-Term Systemic Corticosteroid Use and Related Complications in Patients with Severe Asthma
por: Dalal, Anand A., et al.
Publicado: (2016)

Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA
por: Albers, Frank C., et al.
Publicado: (2019)

Prospective Italian real‐world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports
por: Pini, Laura, et al.
Publicado: (2021)

Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab
por: Pavord, Ian D., et al.
Publicado: (2022)

Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma
por: Gupta, Atul, et al.
Publicado: (2019)

Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO
por: Pavord, Ian D, et al.
Publicado: (2021)

Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis
por: Harrison, Tim, et al.
Publicado: (2020)

Real-World clinical outcomes of asthma patients switched from reslizumab to mepolizumab or benralizumab
por: Walsh, Laura J., et al.
Publicado: (2023)

Characterization of disease flares and impact of mepolizumab in patients with hypereosinophilic syndrome
por: Pane, Fabrizio, et al.
Publicado: (2022)

Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab
por: Pouliquen, Isabelle J., et al.
Publicado: (2015)

The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma
por: Chapman, Kenneth R., et al.
Publicado: (2019)

Real-World Reductions in Oral Corticosteroid Use in the USA Following Mepolizumab Therapy for Severe Asthma
por: Silver, Jared, et al.
Publicado: (2020)

Effectiveness of mepolizumab in severe asthma in Japan: A real‐world study using claims data
por: Nagase, Hiroyuki, et al.
Publicado: (2021)

Pharmacogenetic investigation of efficacy response to mepolizumab in eosinophilic granulomatosis with polyangiitis
por: Condreay, Lynn D., et al.
Publicado: (2020)

Health outcomes after stopping long-term mepolizumab in severe eosinophilic asthma: COMET
por: Liu, Mark C., et al.
Publicado: (2022)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
por: Portacci, Andrea, et al.
Publicado: (2023)

Severe asthma remaining well‐controlled after mepolizumab discontinuation: A case report and literature review
por: Matsuyama, Takahiro, et al.
Publicado: (2023)

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life()
por: Bagnasco, Diego, et al.
Publicado: (2021)

Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics
por: Liu, Mark C., et al.
Publicado: (2021)

Association Between Baseline Therapy and Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome
por: Reiter, Andreas, et al.
Publicado: (2022)

Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months
por: Kayser, Moritz Z, et al.
Publicado: (2021)

Fungal sensitization and its relationship to mepolizumab response in patients with severe eosinophilic asthma
por: Wardlaw, Andrew, et al.
Publicado: (2020)

Real‐world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta‐analysis
por: Charles, David, et al.
Publicado: (2022)

Real-World Experience on the Use of Mepolizumab from the Severe Asthma Registry of the German Asthma Net (MepoGAN-Study)
por: Korn, Stephanie, et al.
Publicado: (2023)

Evaluation of real-world mepolizumab use in severe asthma across Europe: the SHARP experience with privacy-preserving federated analysis
por: Kroes, Johannes A., et al.
Publicado: (2023)

Real-Life Effectiveness of Mepolizumab in Refractory Chronic Rhinosinusitis with Nasal Polyps
por: Domínguez-Sosa, María Sandra, et al.
Publicado: (2023)

From DREAM to REALITI‐A and beyond: Mepolizumab for the treatment of eosinophil‐driven diseases
por: Pavord, Ian D., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hunjocpmpcgqeshvgfpmd1oflm